Luis Meggo Quiroz, MD
Advanced Heart Failure and Transplant Cardiology · Tulsa, OKNPI 1235429549
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,044 of the $18,606 with a category attached, or 70.1%. 21 manufacturers reported payments, led by Abbott at 26.8% of the total.
Across 316 payments — averaging $58.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Ancora Heart, Inc.$4K
- Abiomed$3K
- Alnylam Pharmaceuticals Inc.$2K
- Actelion Pharmaceuticals US, Inc.$786
- E.r. Squibb & Sons, L.L.C.$501
- plus $3K from 15 others
Across 25 payments — averaging $1163.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$21K
- Abbott$8K
What the payments were for
- Travel & lodging$5,44929%
- Food & beverage$13,04470%
- Education$1131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 68 | $4,986 |
| Ancora Heart, Inc. | 25 | $3,847 |
| Abiomed | 34 | $2,687 |
| Alnylam Pharmaceuticals Inc. | 22 | $2,318 |
| Actelion Pharmaceuticals US, Inc. | 17 | $786 |
| E.r. Squibb & Sons, L.L.C. | 22 | $501 |
| Novartis | 45 | $447 |
| United Therapeutics Corporation | 9 | $435 |
| ZOLL Respicardia, Inc. | 2 | $413 |
| Cvrx, Inc. | 6 | $377 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $334 |
| Merck | 7 | $299 |
| Pfizer | 18 | $289 |
| Impulse Dynamics (USA) Inc. | 15 | $269 |
| AstraZeneca | 5 | $195 |
| Edwards Lifesciences | 2 | $164 |
| Akcea Therapeutics, Inc. | 1 | $107 |
| Medtronic | 1 | $71 |
| Boehringer Ingelheim | 2 | $38 |
| Sandoz | 1 | $23 |
| Bayer | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AccuCinch$3,416
- CARDIOMEMS$1,961
- AMVUTTRA$1,735
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,588
- Impella$1,531
- remede System$413
- UPTRAVI$355
- OPSUMIT$355
- Barostim Neo System$250
- ONPATTRO$152
- REMODULIN$124
- CAMZYOS$122
- WAINUA$122
- TEGSEDI$107
- WINREVAIR$104
How this compares
Too few advanced heart failure and transplant cardiology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orenitram ErTreprostinil Diolamine | 32 | $267,706 |
| OpsumitMacitentan | 12 | $152,091 |
| CamzyosMavacamten | 17 | $138,051 |
| JardianceEmpagliflozin | 138 | $122,718 |
| EntrestoSacubitril/Valsartan | 132 | $122,361 |
| EliquisApixaban | 54 | $45,855 |
| FarxigaDapagliflozin Propanediol | 42 | $40,676 |
| Bumetanide | 42 | $2,262 |
| Potassium Chloride | 59 | $1,664 |
| Torsemide | 94 | $1,366 |
| Spironolactone | 202 | $1,331 |
| Eplerenone | 20 | $1,142 |
| Isosorbide Dinitrate | 18 | $1,082 |
| Digoxin | 15 | $923 |
| Metoprolol Succinate | 90 | $860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $786 | $152,09112 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $501 | $138,05117 claims |
| Boehringer IngelheimJardiance | $38 | $122,718138 claims |
| NovartisEntresto | $447 | $122,361132 claims |
| PfizerEliquis | $289 | $45,85554 claims |
| AstraZenecaFarxiga | $195 | $40,67642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Tulsa
- Steven StroudTulsa$39K
- Ralph EnsleyTulsa$11K
- John VannTulsa$9K
- Nina WilliamsTulsa$5K
- Luke CunninghamOklahoma City$70K
- Tarun DasariOklahoma City$2K
- Carol KepfordOklahoma City$716
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.